Cerity Partners
NMRA icon

Cerity Partners’s Neumora Therapeutics NMRA Stock Holding History

Cerity Partners’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$407K Sell
239,653
-20,738
-8% -$39.5K ﹤0.01% 2561
2026
Q1 		$508K Sell
260,391
-14,721
-5% -$38.1K ﹤0.01% 2277
2025
Q4 		$492K Sell
275,112
-13,403
-5% -$29.3K ﹤0.01% 2123
2025
Q3 		$525K Sell
288,515
-35,704
-11% -$57.7K ﹤0.01% 1940
2025
Q2 		$238K Buy
324,219
+21,714
+7% +$16.5K ﹤0.01% 2267
2025
Q1 		$303K Buy
302,505
+58,597
+24% +$100K ﹤0.01% 2011
2024
Q4 		$2.59M Buy
243,908
+1,008
+0.4% +$12.1K 0.01% 992
2024
Q3 		$3.21M Buy
+242,900
New +$2.83M 0.01% 882

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Cerity Partners's NMRA Position: Q2 2026 in Review

Cerity Partners reduced its Neumora Therapeutics (NMRA) stake by 8% in Q2 2026, selling an estimated $39.5K and leaving 239,653 shares worth $407K. The position accounts for ﹤0.01% of the portfolio, ranked #2561.

Cerity Partners first reported a position in NMRA in Q3 2024 and has held it in 8 quarters since. The position peaked at $3.21M in Q3 2024. 100 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Cerity Partners held 239,653 shares of Neumora Therapeutics worth $407K as of Q2 2026.
  • Cerity Partners sold 20,738 Neumora Therapeutics shares in Q2 2026, an estimated $39.5K.
  • Neumora Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2561 holding.
  • Cerity Partners first reported a position in Neumora Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Cerity Partners's Neumora Therapeutics position peaked at $3.21M in Q3 2024.
  • 100 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.